Keywords: idenix, lowers, nm283, dosage, after, ae, reports

Idenix lowers NM283 dosage after AE reports

Article | 03 April 2006

Idenix Pharmaceuticals, a US biopharmaceutical company focused on viral and other infectious diseases, has modified its ongoing Phase IIb hepatitis ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Copegus

Ribavirin

Rebetol

Virazole

Go to drug listing